Serpin Pharma
Serpin Pharma is a biopharmaceutical company dedicated to developing targeted, immune-balancing therapeutics to treat inflammatory diseases. Their lead therapeutic, SP16, is designed to restore immune balance and resolve inflammation, with ongoing preclinical and clinical trials for a broad range of indications including orphan, chronic, and acute diseases. The company aims to shift the inflammatory disease treatment landscape with innovative platform technology and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Injectable SERPIN‑derived peptide program (acute indications: AKI, AMI, CIPN)
An injectable short-peptide therapeutic program designed to modulate inflammation via LRP1 agonism; advanced into Phase II development for select acute indications.
Topical / injectable peptide program (severe skin disease)
Peptide therapeutic formulations intended for inflammatory dermatologic indications with topical and injectable delivery options; program positioned for Phase 2 readiness.
Oral peptide program (autoimmune/inflammatory systemic indications)
Orally delivered peptide program targeting chronic autoimmune and inflammatory disorders in preclinical stages.
Topical peptide program for skin care (licensed)
Peptide formulation licensed for cosmetic/skin-care applications.
SP16
SP16 is a revolutionary therapeutic designed to enhance the body's natural immune response by restoring immune balance and targeting a receptor that mitigates inflammation. It is positioned as a next-generation therapeutic to address a wide range of inflammatory diseases.
SRP-100
Injectable therapeutic in Phase 2 development for Acute Kidney Injury (AKI), Acute Myocardial Infarction (AMI), and Chemotherapy-Induced Neuropathic Pain (CIPN).
Injectable SERPIN‑derived peptide program (acute indications: AKI, AMI, CIPN)
An injectable short-peptide therapeutic program designed to modulate inflammation via LRP1 agonism; advanced into Phase II development for select acute indications.
Topical / injectable peptide program (severe skin disease)
Peptide therapeutic formulations intended for inflammatory dermatologic indications with topical and injectable delivery options; program positioned for Phase 2 readiness.
Oral peptide program (autoimmune/inflammatory systemic indications)
Orally delivered peptide program targeting chronic autoimmune and inflammatory disorders in preclinical stages.
Topical peptide program for skin care (licensed)
Peptide formulation licensed for cosmetic/skin-care applications.
SP16
SP16 is a revolutionary therapeutic designed to enhance the body's natural immune response by restoring immune balance and targeting a receptor that mitigates inflammation. It is positioned as a next-generation therapeutic to address a wide range of inflammatory diseases.
SRP-100
Injectable therapeutic in Phase 2 development for Acute Kidney Injury (AKI), Acute Myocardial Infarction (AMI), and Chemotherapy-Induced Neuropathic Pain (CIPN).
Services
Partnership-based design and execution of early-phase clinical studies, including collaborative trials with academic medical centers and hospitals.
Commercial licensing of peptide-based formulations for applications outside core therapeutic programs (e.g., topical/cosmetic use).
Partnership-based design and execution of early-phase clinical studies, including collaborative trials with academic medical centers and hospitals.
Commercial licensing of peptide-based formulations for applications outside core therapeutic programs (e.g., topical/cosmetic use).
Expertise Areas
- Peptide therapeutic design
- Receptor-targeted anti-inflammatory therapeutics (LRP1)
- Preclinical disease model development and execution
- Clinical trial management (Phase I–IIa)
Key Technologies
- Short therapeutic peptides
- LRP1 receptor agonism
- Rodent and in vivo disease models
- Cell signaling assays (ERK, AKT, NF-kB, JAK/STAT)
News & Updates
The Estée Lauder Companies Inc. announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory peptides can be applied in cosmetics to improve skin health and longevity.
Serpin Pharma, a Virginia-based biopharmaceutical company, has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support the development of SP16-3M for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients.
Serpin Pharma has partnered with Uniklinikum Erlangen in Germany for a Phase IIa clinical trial to evaluate the efficacy and safety of SP163M in preventing acute kidney injury in patients with chronic kidney disease undergoing cardiac surgery.
Serpin Pharma and HekaBio have signed a term sheet to develop and commercialize SP163M, a peptide drug for preventing chemotherapy-induced peripheral neuropathy.
Sanofi’s acquisition of a recombinant alpha-1 antitrypsin (AAT) drug candidate underscores the need for innovative solutions in addressing inflammation. Serpin Pharma’s SP16 platform drug is positioned as a potential transformative treatment.
Serpin Pharma received a $900,000 grant from the BIRD Foundation to support a Phase 2a clinical trial evaluating SP16 in acute myocardial infarction patients, in collaboration with Sheba Medical Center.
The Estée Lauder Companies Inc. announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory peptides can be applied in cosmetics to improve skin health and longevity.
Serpin Pharma, a Virginia-based biopharmaceutical company, has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support the development of SP16-3M for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients.
Serpin Pharma has partnered with Uniklinikum Erlangen in Germany for a Phase IIa clinical trial to evaluate the efficacy and safety of SP163M in preventing acute kidney injury in patients with chronic kidney disease undergoing cardiac surgery.
Serpin Pharma and HekaBio have signed a term sheet to develop and commercialize SP163M, a peptide drug for preventing chemotherapy-induced peripheral neuropathy.
Sanofi’s acquisition of a recombinant alpha-1 antitrypsin (AAT) drug candidate underscores the need for innovative solutions in addressing inflammation. Serpin Pharma’s SP16 platform drug is positioned as a potential transformative treatment.
Serpin Pharma received a $900,000 grant from the BIRD Foundation to support a Phase 2a clinical trial evaluating SP16 in acute myocardial infarction patients, in collaboration with Sheba Medical Center.